Post-Traumatic Stress Disorder (PTSD) Pipeline Overview, Product Review Report 2019

Posted on 2019-10-01 by Mark Hub in Healthcare, Pharmaceuticals // 0 Comments

Albany, US, 2019-Oct-01 — /EPR Network/ —The purpose of this MRH research study titled “Post-Traumatic Stress Disorder (PTSD)-Pipeline Review, H2 2019” is to enlighten the readers about the Post-Traumatic Stress Disorder (PTSD) with a stern focus on the development trends and opportunities projected for future years. In short, this assessment drops light on the market size and revenue share which are motivated by numerous market drivers, together with a clear insight about challenges that might create a blockage for the development of Post-Traumatic Stress Disorder (PTSD)

Get Sample Copy@ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2519478

Post-Traumatic Stress Disorder (PTSD) – Pipeline Review, H2 2019

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Post-Traumatic Stress Disorder (PTSD) – Pipeline Review, H2 2019, provides an overview of the Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline landscape.

Post-traumatic stress disorder (PTSD) is a mental health condition that’s triggered by a terrifying event either experiencing it or witnessing it. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants, anti-anxiety and cognitive therapy.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Post-Traumatic Stress Disorder (PTSD) – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Traumatic Stress Disorder (PTSD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 4, 2, 23, 6 and 1 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 3 and 1 molecules, respectively.

Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
– The pipeline guide reviews pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System)

Request TOC of the Report @ https://www.marketresearchhub.com/report/post-traumatic-stress-disorder-ptsd-pipeline-review-h2-2019-report.html

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Post-Traumatic Stress Disorder (PTSD) – Overview
Post-Traumatic Stress Disorder (PTSD) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Post-Traumatic Stress Disorder (PTSD) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Post-Traumatic Stress Disorder (PTSD) – Companies Involved in Therapeutics Development
Actinogen Medical Ltd
Addex Therapeutics Ltd
Amorsa Therapeutics Inc
Anagin Inc
Aptinyx Inc
Artelo Biosciences Inc
Azevan Pharmaceuticals Inc
Bionomics Ltd
Cannabis Science Inc
Catalyst Pharmaceuticals Inc
Chronos Therapeutics Ltd
Corcept Therapeutics Inc
Eli Lilly and Co
Embera NeuroTherapeutics Inc
Immodulon Therapeutics Ltd
Johnson & Johnson
Lixte Biotechnology Holdings Inc
NeuroNascent Inc
Omeros Corp
Otsuka Holdings Co Ltd
Sanofi
Tonix Pharmaceuticals Holding Corp
Post-Traumatic Stress Disorder (PTSD) – Drug Profiles
(metyrapone + oxazepam) – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ADX-71743 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AM-3506 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BNC-210 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
brexpiprazole – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cannabidiol – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CBISPTSD-001 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPP-115 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CTDP-003 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-107 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IC-87201 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMM-201 – Drug Profile
Product Description
Mechanism Of Action

Continued…………. #@

Enquire about This Report @ https://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=2519478

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports of different sector like Pharmaceuticals market research and analysis. MRH’s expansive collection of industry reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Matched content

Editor’s pick